Cris Jagar, MD
Psychiatry · Pensacola, FLNPI 1538269121
Payments from drug & device makers
Across 626 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Lundbeck LLC$803
- Teva Pharmaceuticals USA, Inc.$727
- Takeda Pharmaceuticals U.S.A., Inc.$695
- Corium, LLC$691
- plus $5K from 28 others
What the payments were for
- Food & beverage$9,43597%
- Education$3373%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 103 | $1,151 |
| Otsuka America Pharmaceutical, Inc. | 78 | $1,071 |
| Lundbeck LLC | 52 | $803 |
| Teva Pharmaceuticals USA, Inc. | 48 | $727 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $695 |
| Corium, LLC | 38 | $691 |
| Alkermes, Inc. | 31 | $609 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $576 |
| Neos Therapeutics, LP | 24 | $467 |
| Axsome Therapeutics, Inc. | 16 | $344 |
| Ironshore Pharmaceuticals Inc. | 25 | $335 |
| Johnson & Johnson | 19 | $311 |
| Tris Pharma Inc | 16 | $255 |
| Almatica Pharma LLC | 11 | $232 |
| Lilly USA, LLC | 10 | $193 |
| Supernus Pharmaceuticals, Inc. | 11 | $180 |
| Avanir Pharmaceuticals, Inc. | 7 | $145 |
| Vanda Pharmaceuticals Inc. | 6 | $138 |
| Shire North American Group Inc | 15 | $136 |
| Sunovion Pharmaceuticals Inc. | 9 | $119 |
| Eisai Inc. | 6 | $104 |
| E.r. Squibb & Sons, L.L.C. | 5 | $82 |
| Adlon Therapeutics L.p. | 6 | $74 |
| Bausch Health US, LLC | 3 | $52 |
| Jazz Pharmaceuticals Inc. | 3 | $48 |
| Neurocrine Biosciences, Inc. | 1 | $37 |
| Neuronetics, Inc. | 1 | $32 |
| Alfasigma USA, Inc. | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Boston Scientific | 2 | $25 |
| Aytu Biopharma, Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $22 |
| Sage Therapeutics, LLC | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $18 |
How this compares
$9,772 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 27 | $25,245 |
| RexultiBrexpiprazole | 12 | $17,641 |
| Lisdexamfetamine Dimesylate | 30 | $5,640 |
| Bupropion XlBupropion Hcl | 151 | $5,148 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 209 | $4,867 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 63 | $4,746 |
| Duloxetine Hcl | 166 | $3,893 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 102 | $3,863 |
| Aripiprazole | 72 | $3,462 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 11 | $2,636 |
| Clonazepam | 201 | $2,244 |
| Quetiapine Fumarate | 94 | $2,157 |
| Vilazodone Hcl | 16 | $2,029 |
| Trazodone Hcl | 156 | $2,022 |
| Alprazolam | 216 | $1,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $695 | $25,24527 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,071 | $17,64112 claims |
| Lilly USA, LLCOlanzapine | $193 | $1,00915 claims |
| Almatica Pharma LLCSertraline Hcl | $232 | $43666 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Pensacola
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.